Thrombosis Drugs Market Size (2024 - 2029)

Thrombosis Drugs Market Analysis

The Thrombosis Drugs Market size is estimated at USD 24.20 billion in 2024, and is expected to reach USD 35.70 billion by 2029, growing at a CAGR of 8% during the forecast period (2024-2029).

The market is primarily driven by the increase in the geriatric and obese population, the rising burden of cardiovascular diseases and trauma cases, and the technological advancement in hematology. For instance, according to the World Population Aging Report 2023, developed countries are expected to move to a more advanced stage of population aging, with the proportion of older persons rising from 20% in 2023 to 28% in 2050. For other developing countries, this proportion is expected to rise from 9% to 17%. Least developing countries, while still at a lower level, are expected to experience a more rapid increase of about 180% from nearly 4% to over 6% during this period. Since the older population is prone to the disease, it is expected to generate the need for these drugs for treatment, thereby driving the market's growth.

The increasing burden of obesity has also changed significantly in the last decade globally. Developed and emerging markets are having significant issues controlling the associated diseases. For instance, according to the September 2023 published CDC data, in 2022, 22 states in the US reported an adult obesity prevalence of 35% or higher, compared to 19 states in the previous year. Thus, with the increase in the obese population, the demand for thrombotic drugs is expected to increase over the forecast period, as obesity is a significant cause of vascular diseases.

The strategic activities of the market players, such as research and development activities and product launches, are expected to contribute to market growth over the forecast period. For instance, in February 2023, Bayer announced that first patients had been enrolled in the initial trials for its OCEANIC clinical trial program, designed to explore the use of asundexian (BAY2433334), an investigational oral Factor XIa (FXIa) inhibitor, in patients with atrial fibrillation (AF) and in patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA), a temporary period of symptoms similar to those of a stroke. In July 2022, the Food and Drug Administration (FDA) granted abelacimab, a new drug from Anthos Therapeutics, a fast-track designation to treat cancer-related thrombosis.

However, a lack of awareness about venous thromboembolism conditions and the side effects associated with thrombosis drugs may restrain the market's growth over the forecast period.

Thrombosis Drugs Industry Segmentation

As per the scope of the report, a thrombus is a blood clot that develops on the inside of the heart or on the walls of blood vessels as a result of the adhesion of blood platelets, proteins, and cells. Thrombosis is considered to be the major source of morbidity and mortality among elderly patients. It has been established that thrombosis is caused due to certain cardiovascular disorders as a result of old age or obesity.

The thrombosis drugs market is segmented by drug class, disease type, distribution channel, and geography. By drug class, the market is segmented as factor Xa Inhibitor, Heparin, P2Y12 Platelet Inhibitor, and other drug classes. By disease type, the market is segmented as pulmonary embolism, atrial fibrillation, deep vein thrombosis, and other disease types. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. By geography, the market is segmented as North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD) for the above segments.